CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer
CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer
复制标题
CA19-9 与甲基化 HOXA1 和 SST 结合可用于诊断 I 期胰腺癌
作者：
Suehiro Yutaka;Suenaga Shigeyuki;Kunimune Yuki;Yada Shoko;Hamamoto Kaori;Tsuyama Takanori;Amano Shogo;Matsui Hiroto;Higaki Shingo;Fujii Ikuei;Suzuki Chieko;Hoshida Tomomi;Matsumoto Toshihiko;Fujimoto Yuko;Kaino Seiji;Shinjo Keiko;Kondo Yutaka;Sakaida Isao
我们以前建立了一种新的甲基化检测方法，即联合限制性数字聚合酶(CORD)方法，包括甲基化敏感的限制性内切酶处理DNA和滴状数字PCR。方法在本研究中，我们使用82例健康人、13例良性胰腺疾病、3例分支导管内乳头状黏液瘤和91例胰腺癌患者的血清标本，评估了血清甲基化同源盒A1(MHOXA1)和甲基化生长抑素(MSST)对胰腺癌诊断的敏感性和特异性分别为71.4%、71.4%和71.4%CA19-9为50.0%，CA19-9为94.9%；MHOXA1分别为51.6%、68.8%和90.8%；mSST分别为50.1%、68.8%和94.9%。MHOXA1和CA19-9联合检测的符合率分别为86.8%、81.3%和85.7%；mSST和CA19-9联合检测的符合率分别为86.8%、87.5%和89.8%；三项联合检测的符合率分别为89.0%、87.5%和85.7%。
IntroductionWe previously developed a novel methylation assay, the combined restriction digital PCR (CORD) assay, consisting of treatment of DNA with methylation-sensitive restriction enzymes and droplet digital PCR.MethodsIn this study, we assessed the diagnostic performance of serum methylated Homeobox A1 (mHOXA1) and methylated somatostatin (mSST) using the CORD assay in combination with CA19-9 for pancreatic cancer using serum samples from 82 healthy individuals, 13 patients with benign pancreatic disease, 3 patients with branched-duct intraductal papillary mucinous neoplasm, and 91 patients with pancreatic cancer.ResultsFor the single marker tests, sensitivity for all stages of pancreatic cancer, stage I cancer, and specificity were, respectively, 71.4%, 50.0%, and 94.9% for CA19-9; 51.6%, 68.8%, and 90.8% for mHOXA1; and 50.1%, 68.8%, and 94.9% for mSST. Those for the combined marker tests were, respectively, 86.8%, 81.3%, and 85.7% for combined mHOXA1 and CA19-9; 86.8%, 87.5%, and 89.8% for combined mSST and CA19-9; and 89.0%, 87.5%, and 85.7% for all three markers combined.ConclusionThe combination of mHOXA1 and mSST with CA19-9 appears to be useful to detect pancreatic cancer even at an early stage.
登录
查看更多内容
影响因子：
5.2
作者：
Hideura, Eizaburou;Suehiro, Yutaka;Yamasaki, Takahiro
通讯作者：
Yamasaki, Takahiro
DOI：
10.1126/science.aar3247
发表时间：
2018-02-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Cohen JD;Li L;Wang Y;Thoburn C;Afsari B;Danilova L;Douville C;Javed AA;Wong F;Mattox A;Hruban RH;Wolfgang CL;Goggins MG;Dal Molin M;Wang TL;Roden R;Klein AP;Ptak J;Dobbyn L;Schaefer J;Silliman N;Popoli M;Vogelstein JT;Browne JD;Schoen RE;Brand RE;Tie J;Gibbs P;Wong HL;Mansfield AS;Jen J;Hanash SM;Falconi M;Allen PJ;Zhou S;Bettegowda C;Diaz LA Jr;Tomasetti C;Kinzler KW;Vogelstein B;Lennon AM;Papadopoulos N
通讯作者：
Papadopoulos N
影响因子：
2.5
作者：
Poruk KE;Gay DZ;Brown K;Mulvihill JD;Boucher KM;Scaife CL;Firpo MA;Mulvihill SJ
通讯作者：
Mulvihill SJ
粪便 DNA 检测与粪便血红蛋白免疫化学检测相结合，有助于检测结直肠晚期腺瘤
DOI：
--
发表时间：
2019
期刊：
影响因子：
--
作者：
Yutaka Suehiro;Takahiro Yamasaki
通讯作者：
Takahiro Yamasaki